TRACON Pharmaceuticals To Present At The Rodman & Renshaw 21st Annual Global Investment Conference Sponsored By H.C. Wainwright

On September 3, 2019 TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., reported that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright in New York on Monday, September 9th, at 3:50pm EDT (Press release, Tracon Pharmaceuticals, SEP 3, 2019, View Source [SID1234539211]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentations" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

Selecta Biosciences to Present at the Janney Healthcare Conference

On September 3, 2019 Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Janney Healthcare Conference in New York on Monday, September 9 at 9:55 a.m. Eastern Time (Press release, Selecta Biosciences, SEP 3, 2019, View Source [SID1234539210]). A live webcast of the presentation will be available on the Investors & Media section of the Selecta website at www.selectabio.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress

On September 3, 2019 Incyte (Nasdaq:INCY) reported that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019 (Press release, Incyte, SEP 3, 2019, View Source [SID1234539209]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and efficacy data in patients with FGFR2 fusions or rearrangements, as well as genomic profiling and correlations with clinical outcomes will be presented. Results from the Phase 1 study of INCB001158, an arginase inhibitor being developed with Calithera Biosciences, alone and in combination with pembrolizumab as a treatment for advanced or metastatic solid tumors, will also be presented.

"Incyte is committed to advancing treatments that have the potential to address areas of high unmet need and we look forward to sharing data on our investigational therapies with the oncology community at ESMO (Free ESMO Whitepaper) 2019," said Steven Stein, M.D., Chief Medical Officer, Incyte. "Data from the Phase 2 FIGHT-202 study assessing pemigatinib as a potential treatment for cholangiocarcinoma are encouraging and may represent an important step forward for patients in urgent need of effective treatment options."

Abstracts will be available on the ESMO (Free ESMO Whitepaper) Congress website at View Source

Oral Presentations:

FIGHT-202: a Phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) (Abstract #2550, proffered paper session)

Friday, September 27, 2019 from 3:00 p.m. CEST to 3:15 p.m. CEST (9 a.m. ET to 9:15 a.m. ET) in Madrid Auditorium (Hall 2)
Phase 1 study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (Adv/Met) solid tumors (Abstract #1621, oral abstract session)

Sunday, September 29, 2019 from 4:54 p.m. CEST to 5:06 p.m. CEST (10:54 a.m. ET to 11:06 a.m. ET) in Malaga Auditorium (Hall 5)
Poster Details:

Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the FIGHT-202 trial (Abstract #2078, poster session)

Sunday, September 29, 2019 from 12:00 p.m. CEST to 1:00 p.m. CEST (6:00 a.m. ET to 7:00 a.m. ET) in Poster Area (Hall 4)
Full session details and data presentation listings for ESMO (Free ESMO Whitepaper) 2019 can be found at: View Source

Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month

On September 3, 2019 Incyte (NASDAQ:INCY) is proud to further elevate awareness of myeloproliferative neoplasms (MPNs) throughout the month of September in honor of Blood Cancer Awareness Month and support the MPN community in recognizing MPN Awareness Day on September 12 (Press release, Incyte, SEP 3, 2019, View Source [SID1234539208]). MPNs are a closely related group of rare, chronic blood cancers, which include myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), affecting an estimated 200,000 people in the U.S.i They occur when the bone marrow that produces the body’s blood cells functions abnormally.ii

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To activate, inspire and support the MPN community, Incyte encourages people living with an MPN, as well as their caregivers and loved ones, to take action by participating in the #MyMPNChallenge. Every Monday throughout the month of September, Voices of MPN will post a new challenge to its Facebook and Twitter pages. This is a series of simple but meaningful activities to challenge people impacted by MPNs to take steps to educate themselves and increase awareness of MPNs. To further support the community, for every challenge completed, Incyte will make a donation to The Leukemia & Lymphoma Society. To learn more about these activities or to participate, visit Voices of MPN.

"The symptoms of MPNs are often unrecognized and underappreciated, but the burden on patients can be severe," said Hervé Hoppenot, Chief Executive Officer, Incyte. "By raising awareness of MPNs and offering educational resources through initiatives like the #MyMPNChallenge, we hope to further empower patients diagnosed with an MPN to take a more active role in managing their condition and equip them with the tools they need to have informed conversations with their healthcare professional."

In addition to participating in the #MyMPNChallenge social media campaign, people living with MPNs, physicians, caregivers and advocates are encouraged to show their support and help raise awareness of these rare diseases through a variety of activities on MPN Awareness Day and throughout the month of September, including:

Nominate your MPN Hero: Honor a person or organization that has dedicated themselves to improving the lives of people with MPNs by the September 12 deadline here.
Use the MPN Awareness Social Media Photo Filter: Help raise awareness of MPNs by adding a custom frame to your Facebook profile picture or share an inspirational message using a custom Facebook photo filter. Visit Voices of MPN on Facebook to learn more.
Change the Way We See MPNs: Over the course of the month, Voices of MPN will share three different patient stories highlighting the impact MPNs can have on patients’ lives. Visit VoicesofMPN.com to learn more about their stories and MPNs.
Stay connected and informed about all of the MPN awareness activities by "Liking" the "Voices of MPN" Facebook page, following "Voices of MPN" on Pinterest, following "Voices of MPN" on Twitter or using the hashtag #MyMPNChallenge. Visit VoicesofMPN.com to access helpful resources about living with MPNs, including the MPN Tracker Tools, designed to help track MPN symptoms, blood cell counts and procedures.

About Myeloproliferative Neoplasms

Myeloproliferative neoplasms (MPNs) are a closely related group of blood cancers in which the bone marrow functions abnormally. The bone marrow is where the body’s blood cells are made. MPNs are progressive blood cancers that can strike anyone at any age, but they are more common in older adults. Estimates of the prevalence of MPNs vary, but analysis of claims data suggests there may be as many as 200,000 people in the U.S. living with MF, PV or ET.i

PHIO PHARMACEUTICALS TO PRESENT AT THE H.C. WAINWRIGHT 21ST ANNUAL HEALTHCARE CONFERENCE

On September 3, 2019 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, announced today that it will present at the H.C. Wainwright 21st Annual Healthcare Conference in New York City (Press release, Phio Pharmaceuticals, SEP 3, 2019, View Source [SID1234539207]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Gerrit Dispersyn, Dr. Med. Sc., President and CEO, will present an overview of the Company’s RNAi technology and an update on the Company’s development activities. The presentation will be held September 10, 2019, at 11:40 AM in the Kennedy II room (4th Floor) at the Lotte New York Palace Hotel. Dr. Dispersyn will also be available for investor and executive meetings throughout the conference.

The presentation will be webcast live and archived under the "Investors – Events and Presentations" section of the Company’s website, www.phiopharma.com.